What do clinicians need to watch for with direct-acting antiviral therapy?

Author:

Aghemo Alessio12,Piroth Lionel3,Bhagani Sanjay4

Affiliation:

1. Department of Biomedical Sciences; Humanitas University; Pieve Emanuele Milan Italy

2. Division of Internal Medicine and Hepatology; Humanitas Clinical and Research Center; Rozzano Milan Italy

3. Infectious Diseases Department; University Hospital; INSERM; Dijon France

4. Department of Infectious Diseases/HIV Medicine; Royal Free London Foundation Trust; Research Department of Infection; UCL; London UK

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health

Reference41 articles.

1. Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES;Butt;Liver Int,2016

2. Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis;Preda;Liver Int,2017

3. New horizons in hepatitis C antiviral therapy with direct-acting antivirals;Aghemo;Hepatology,2013

4. New hepatitis C therapies: the toolbox, strategies, and challenges;Pawlotsky;Gastroenterology,2014

5. EASL recommendations on treatment of hepatitis C 2016;European Association for the Study of the Liver;J Hepatol,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3